Kk. Ang et al., Activation of spinal opioid receptors contributes to hypotension after hemorrhage in conscious rats, AM J P-HEAR, 45(5), 1999, pp. H1552-H1558
Citations number
28
Categorie Soggetti
Cardiovascular & Hematology Research
Journal title
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
Opioid receptors are activated during severe hemorrhage, resulting in sympa
thoinhibition and a profound fall in blood pressure. This study examined th
e location and subtypes of opioid receptors that might contribute to hypote
nsion after hemorrhage. Intrathecal naloxone methiodide (100 nmol) abolishe
d the fall in blood pressure after hemorrhage (1.5% of body wt; mean arteri
al pressure 122 +/- 8 mmHg after naloxone methiodide vs. 46 +/- 5 mmHg in c
ontrols, P < 0.001). Intracisternal naloxone methiodide was less effective
than intrathecal naloxone methiodide, whereas intravenous naloxone methiodi
de, which does not cross the blood-brain barrier, did not alter the fall in
blood pressure after hemorrhage. These results demonstrate that spinal opi
oid receptors contribute to hypotension after hemorrhage but do not exclude
supraspinal effects. In separate experiments, the subtype-specific opioid
antagonists ICI-174864 (delta-antagonist), norbinaltorphimine (nor-BNI; kap
pa-antagonist), and H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP; mu-ant
agonist) were each administered intrathecally to determine the minimum dose
that would attenuate hypotension during severe hemorrhage. These antagonis
ts were effective at similar doses (3 nmol for CTOP, 6 nmol for ICI-174864,
and 10 nmol for nor-BNI), although the binding affinities of these three d
ifferent agents for their target receptors varied >1600-fold. Comparisons o
f the minimum effective doses of these antagonists in relation to their bin
ding affinities provides strong evidence for the participation of delta-rec
eptors in mediating hypotension after hemorrhage. In contrast, the dose at
which nor-BNI was effective suggests an effect at delta-receptors but not k
appa-receptors. The efficacy of CTOP, albeit at a high dose, also suggests
an effect at mu-receptors.